My Portfolio

Biogen Inc BIIB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 4:07 PM EDT

195.96UNCH (UNCH)

Volume

22,129

195.96

+7.13 (+3.78%)

Volume

869,232

52 week range

121.05 - 205.97

Open187.69
Day High196.51
Day Low187.48
Prev Close188.83
52 Week High205.97
52 Week High Date05/13/26
52 Week Low121.05
52 Week Low Date07/21/25

Latest On Biogen Inc

How 4 Americans navigate the emotional and financial costs of ALSMay 14, 2026CNBC.com
Stocks making the biggest moves midday: Ford, Cisco, Applied Materials & moreMay 14, 2026CNBC.com
Biogen advances Alzheimer's drug to late-stage trial despite disappointing dataMay 14, 2026CNBC.com
Stocks making the biggest moves premarket: Versant, Biogen, Bullish, Cisco, moreMay 14, 2026CNBC.com
Eli Lilly shares surge on a beat-and-raise, proving the stock's swoon was a mistakeApril 30, 2026CNBC.com
Jim Cramer's top 10 things to watch in the stock market WednesdayApril 29, 2026CNBC.com
Dow slides more than 250 points, posting a fifth day of losses, as oil prices riseApril 28, 2026CNBC.com
WHCD shooting, DOJ ends Powell probe and more: Morning SquawkApril 27, 2026CNBC.com
'Mag 7' earnings, Fed meeting will test a stock market near all-time highs. Here's what's aheadApril 24, 2026CNBC.com
Wednesday's big analyst calls: Nvidia, Apple, Tesla, Cava, Netflix, Cava, AirbnbApril 22, 2026CNBC.com

Key Stats

Market Cap28.931B
Shares Out147.64M
10 Day Average Volume1.06M
Dividend-
Dividend Yield-
Beta0.18

Latest On Biogen Inc

How 4 Americans navigate the emotional and financial costs of ALSMay 14, 2026CNBC.com
Stocks making the biggest moves midday: Ford, Cisco, Applied Materials & moreMay 14, 2026CNBC.com
Biogen advances Alzheimer's drug to late-stage trial despite disappointing dataMay 14, 2026CNBC.com
Stocks making the biggest moves premarket: Versant, Biogen, Bullish, Cisco, moreMay 14, 2026CNBC.com
Eli Lilly shares surge on a beat-and-raise, proving the stock's swoon was a mistakeApril 30, 2026CNBC.com
Jim Cramer's top 10 things to watch in the stock market WednesdayApril 29, 2026CNBC.com
Dow slides more than 250 points, posting a fifth day of losses, as oil prices riseApril 28, 2026CNBC.com
WHCD shooting, DOJ ends Powell probe and more: Morning SquawkApril 27, 2026CNBC.com
'Mag 7' earnings, Fed meeting will test a stock market near all-time highs. Here's what's aheadApril 24, 2026CNBC.com
Wednesday's big analyst calls: Nvidia, Apple, Tesla, Cava, Netflix, Cava, AirbnbApril 22, 2026CNBC.com

KEY STATS

Open187.69
Day High196.51
Day Low187.48
Prev Close188.83
52 Week High205.97
52 Week High Date05/13/26
52 Week Low121.05
52 Week Low Date07/21/25
Market Cap28.931B
Shares Out147.64M
10 Day Average Volume1.06M
Dividend-
Dividend Yield-
Beta0.18

RATIOS/PROFITABILITY

EPS (TTM)9.32
P/E (TTM)21.03
Fwd P/E (NTM)13.34
EBITDA (TTM)3.399B
ROE (TTM)7.70%
Revenue (TTM)9.937B
Gross Margin (TTM)75.49%
Net Margin (TTM)13.81%
Debt To Equity (MRQ)33.72%

EVENTS

Earnings Date07/29/2026(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Content From Our Affiliates

Biogen, UCB publishes full results from PHOENYCS GO clinical trial in The LancetJune 1, 2026TipRanks
Biogen and Denali’s BIIB122 Parkinson’s Trial Completion Sets Up Key Catalyst for InvestorsMay 29, 2026TipRanks
Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Biogen (BIIB)May 29, 2026TipRanks
Biogen price target raised to $227 from $222 at RBC CapitalMay 27, 2026TipRanks
RBC Capital Reaffirms Their Buy Rating on Biogen (BIIB)May 27, 2026TipRanks

Profile

Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States...

Caroline Dorsa

Independent Chairman of the Board

Maria Freire Ph.D.

Independent Chairman of the Board

Christopher Viehbacher

President, Chief Executive Officer, Director

Robin Kramer

Chief Financial Officer, Executive Vice President

Sean Godbout

Chief Accounting Officer, Vice President, Global Corporate Controller, Principal Accounting Officer

Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

Address

225 Binney Street

Cambridge, MA

02142

United States

https://www.biogen.com/